Clinical Trials

Neuroendocrinologic Tumors

Recruitment stopped
Ongoing Recruitment

EVINEC [Rekrutierung nach Rücksprache]

(second-line)
Title:Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Indication:Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung; Well to moderately differentiated neuroendocrine carcinoma (NET G1 / G2) that switched to G3 (confirmed by histology); Neuroendocrine tumor G3 (NET G3)
Type of study:Phase II
Contact: Julia Weck (Study Nurse)
[julia.weck@med.uni-heidelberg.de]
Investigator: Dr. med. Leonidas Apostolidis (Prüfer)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT02113800
EudraCT: 2012-004550-28 (siehe EU klinisches Studienregister)

NCT-PMO-1603 TOP-ART

(second-line, BRCAness)
Title:A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Indication:DNA Repair-Deficiency Disorders
Type of study:Phase II
Contact: Barbara Stöhr (Study Nurse)
[barbara.stoehr@nct-heidelberg.de]
Investigator: Prof. Dr. Stefan Fröhling (Leiter klinische Prüfung)
Trial Register: Die Studie ist bei den "U.S. National Institutes of Health" (ClinicalTrials.gov) registriert. Siehe NCT03127215
EudraCT: 2017-001755-31 (siehe EU klinisches Studienregister)

AveNEC [Rekrutierung nach Rücksprache]

Title:A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first line chemotherapy (AveNEC)
Indication:Patients with advanced neuroendocrine carcinomas NEC G3 (WHO 2010) (excluding SCLC and Merkel cell carcinomas) who experienced tumor progression within 9 months after prior chemotherapy
Type of study:Phase II
Contact: Julia Weck (Study Nurse)
[julia.weck@med.uni-heidelberg.de]
Investigator: Dr. med. Leonidas Apostolidis (Leiter klinische Prüfung)
Trial Register: No trial registry number given.
EudraCT: 2016-004373-40 (siehe EU klinisches Studienregister)

STARTRK-2/ RXDX-101-92

Title:AN OPEN-LABEL, MULTICENTER, GLOBAL PHASE 2 BASKET STUDY OF ENTRECTINIB FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS THAT HARBOR NTRK1/2/3, ROS1, OR ALK GENE REARRANGEMENTS
Indication:Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Type of study:Phase II
Contact: Stefanie Hofmann (Study Nurse)
[stefanie.hofmann@med.uni-heidelberg.de]
Investigator: Dr. med. Christoph Springfeld (Prüfer)
Trial Register: No trial registry number given.
EudraCT: 2015-003385-84 (siehe EU klinisches Studienregister)